Dr Philip Molyneaux is a Clinical Senior Lecturer in Interstitial lung disease and an Honorary Consultant at the Royal Brompton Hospital, where he is the director of the Clinical Research Facility.
Philip qualified from Guy's, King's and St Thomas' School of Medicine in 2004, where he completed an intercalated BSc. in Molecular Genetics. He undertook his SHO training at Guy’s and St Thomas’ and upon completion of the MRCP attained an NIHR Academic Clinical Fellow position in Respiratory medicine at Imperial College. He spent the next two years training at St Mary’s Hospital and working with Professors Cookson, Moffatt and Johnston studying the respiratory microbiome in COPD.
An Asmarley training fellowship allowed him to undertake a PhD examining the host response to the respiratory microbiome in Idiopathic Pulmonary Fibrosis as part of the Prospective Study of Fibrosis In the Lung Endpoints (PROFILE) study with Professor Maher.
Having completed his clinical training in Respiratory and Critical Care Medicine he returned to Imperial joining the Fibrosis Research Group as a Senior Clinical Lecturer. He was awarded the Action for Pulmonary Fibrosis Mike Bray Fellowship which enabled him to establish his research group studying the interaction between the respiratory tract microbiota and innate immunity in pulmonary fibrosis. He is Associate Editor at European Respiratory Journal Open Research and BMC Pulmonary Medicine. He sits on the British Thoracic Society Science and Advisory board as well as the ILD Registry committee.
Molyneaux PL, 2021, The microbiome in IPF: tissue is not the issue, Thorax, Vol:76, ISSN:0040-6376, Pages:218-218
et al., 2021, The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis., Am J Respir Crit Care Med, Vol:203, Pages:339-347
et al., 2021, Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis, American Journal of Respiratory and Critical Care Medicine, ISSN:1073-449X
et al., 2021, Persistent post-COVID-19 inflammatory interstitial lung disease: an observational study of corticosteroid treatment, Annals of the American Thoracic Society, ISSN:2329-6933
et al., 2020, Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression, Respirology, ISSN:1323-7799, Pages:1-8